



State-of-the-Art Cancer Immunotherapies—2nd Edition

Guest Editors:

Prof. Dr. Takayuki Yoshimoto

Department of Immunoregulation, Institute of Medical Science, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan

Dr. Takuma Kato

Department of Cellular and Molecular Immunology, Mie University Graduate School of Medicine, 2-174 Esobashi, Tsu, Mie 514-8507, Japan

Dr. Hisashi Nagase

Department of Infection and Host Defense, Shinshu University School of Medicine, 3-1-1, Asahi, Matsumoto 390-8621, Japan

Deadline for manuscript submissions:

closed (20 August 2025)

Message from the Guest Editors

Dear Colleagues,

The current global success in the protection against COVID-19 through vaccination has proved the effectiveness and safety of the mRNA vaccine delivered by lipid nanoparticles. Such breakthroughs, including cancer vaccination; adoptive cell transfer therapy using CAR-T cells, TCR-T cells, and iPS cell-derived cells; immune checkpoint inhibitors; antibody therapy; dendritic cell therapy; and molecular targeting therapy, have greatly improved cancer patient outcomes. However, the overall survival rate is still unsatisfactory; therefore, it is necessary to much better understand the molecular mechanisms of cancer development and progression in the immunosuppressive tumor microenvironment.

In this Special Issue, we will focus on the latest advances in research on cancer immunotherapy ranging from basic research to clinical aspects that may advance our understanding of human cancer. Since IJMS is a journal of molecular science, pure clinical studies such as case reports will not be suitable for submission, but clinical submissions such as biomolecular experiments are welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. José L. Quiles

Department of Physiology,
Institute of Nutrition and Food
Technology “Jose Mataix”,
Biomedical Research Center,
University of Granada, Avda.
Conocimiento s/n, 18100 Armilla,
Granada, Spain

Message from the Editor-in-Chief

The *International Journal of Molecular Sciences (IJMS)* is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, and molecular biophysics. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Contact Us

*International Journal of Molecular
Sciences* Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/ijms
ijms@mdpi.com
X@IJMS_MDPI